PreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology Officer
PreveCeutical Medical Inc. (OTCQB: PRVCF) has appointed Dr. Francis Tavares as Chief Technology Officer, effective June 27, 2025. Dr. Tavares brings over three decades of experience in organic and medical chemistry, and drug discovery to the company.
Dr. Tavares most recently served as President and CEO of ChemoGenics BioPharma, where he led drug discovery initiatives resulting in the commercialization of Trilaciclib and successful Phase 3 clinical trials of Lerociclib, a CDK4/6 inhibitor. His career includes significant achievements at GlaxoSmithKline, where he received the Excellence in Science Award in 2004, and the successful establishment of ChemoGenics BioPharma.
The appointment strengthens PreveCeutical's leadership team as the company continues its development of preventive and curative therapies using organic and nature-identical products.
PreveCeutical Medical Inc. (OTCQB: PRVCF) ha nominato il Dr. Francis Tavares come Chief Technology Officer, con effetto dal 27 giugno 2025. Il Dr. Tavares porta con sé oltre trent'anni di esperienza in chimica organica e medica, oltre che nella scoperta di farmaci.
Recentemente, il Dr. Tavares ha ricoperto il ruolo di Presidente e CEO di ChemoGenics BioPharma, dove ha guidato iniziative di scoperta di farmaci che hanno portato alla commercializzazione di Trilaciclib e al successo delle sperimentazioni cliniche di Fase 3 di Lerociclib, un inibitore CDK4/6. La sua carriera include importanti risultati presso GlaxoSmithKline, dove ha ricevuto il premio Excellence in Science nel 2004, e la fondazione di successo di ChemoGenics BioPharma.
Questa nomina rafforza il team di leadership di PreveCeutical mentre l'azienda continua a sviluppare terapie preventive e curative utilizzando prodotti organici e identici a quelli naturali.
PreveCeutical Medical Inc. (OTCQB: PRVCF) ha nombrado a Dr. Francis Tavares como Director de Tecnología, con efecto a partir del 27 de junio de 2025. El Dr. Tavares aporta más de tres décadas de experiencia en química orgánica y médica, así como en el descubrimiento de fármacos.
Recientemente, el Dr. Tavares se desempeñó como Presidente y CEO de ChemoGenics BioPharma, donde lideró iniciativas de descubrimiento de medicamentos que resultaron en la comercialización de Trilaciclib y en exitosos ensayos clínicos de Fase 3 de Lerociclib, un inhibidor CDK4/6. Su carrera incluye logros significativos en GlaxoSmithKline, donde recibió el premio Excellence in Science en 2004, y la exitosa creación de ChemoGenics BioPharma.
Este nombramiento fortalece el equipo directivo de PreveCeutical mientras la empresa continúa desarrollando terapias preventivas y curativas utilizando productos orgánicos e idénticos a los naturales.
PreveCeutical Medical Inc. (OTCQB: PRVCF)는 2025년 6월 27일부로 프란시스 타바레스 박사를 최고기술책임자(CTO)로 임명했습니다. 타바레스 박사는 유기 및 의약 화학, 신약 개발 분야에서 30년 이상의 경험을 보유하고 있습니다.
타바레스 박사는 최근 ChemoGenics BioPharma의 사장 겸 CEO로 재직하며, Trilaciclib의 상용화와 CDK4/6 억제제인 Lerociclib의 성공적인 3상 임상시험을 이끄는 신약 개발 프로젝트를 주도했습니다. 그는 GlaxoSmithKline에서 2004년 과학 우수상(Excellence in Science Award)을 수상하는 등 다수의 성과를 거두었으며, ChemoGenics BioPharma의 성공적인 설립에도 기여했습니다.
이번 임명은 PreveCeutical이 유기 및 자연 동일 제품을 활용한 예방 및 치료용 치료제 개발을 지속하는 가운데, 경영진을 강화하는 계기가 될 것입니다.
PreveCeutical Medical Inc. (OTCQB : PRVCF) a nommé le Dr Francis Tavares au poste de Directeur Technique, à compter du 27 juin 2025. Le Dr Tavares apporte plus de trente ans d'expérience en chimie organique et médicale ainsi qu'en découverte de médicaments.
Le Dr Tavares a récemment été Président et CEO de ChemoGenics BioPharma, où il a dirigé des initiatives de découverte de médicaments ayant conduit à la commercialisation de Trilaciclib et à des essais cliniques de phase 3 réussis de Lerociclib, un inhibiteur CDK4/6. Sa carrière comprend des réalisations majeures chez GlaxoSmithKline, où il a reçu le prix Excellence in Science en 2004, ainsi que la création réussie de ChemoGenics BioPharma.
Cette nomination renforce l'équipe de direction de PreveCeutical alors que l'entreprise poursuit le développement de thérapies préventives et curatives utilisant des produits organiques et identiques à ceux de la nature.
PreveCeutical Medical Inc. (OTCQB: PRVCF) hat Dr. Francis Tavares zum Chief Technology Officer ernannt, gültig ab dem 27. Juni 2025. Dr. Tavares bringt über drei Jahrzehnte Erfahrung in organischer und medizinischer Chemie sowie in der Wirkstoffforschung mit.
Dr. Tavares war zuletzt Präsident und CEO von ChemoGenics BioPharma, wo er Forschungsinitiativen leitete, die zur Kommerzialisierung von Trilaciclib und erfolgreichen Phase-3-Studien von Lerociclib, einem CDK4/6-Inhibitor, führten. Seine Karriere umfasst bedeutende Erfolge bei GlaxoSmithKline, wo er 2004 den Excellence in Science Award erhielt, sowie die erfolgreiche Gründung von ChemoGenics BioPharma.
Die Ernennung stärkt das Führungsteam von PreveCeutical, während das Unternehmen weiterhin präventive und kurative Therapien mit organischen und naturidentischen Produkten entwickelt.
- Appointment of highly experienced CTO with over 30 years in drug discovery and development
- New CTO has proven track record of successful drug commercialization (Trilaciclib)
- Dr. Tavares brings extensive experience in leading Phase 1-3 clinical trials
- Strong background in securing venture capital and SBIR grants
- None.
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to have appointed Dr. Francis Tavares as a corporate advisor effective 27 June, 2025.
Stephen Van Deventer, CEO of PreveCeutical, commented:
"We are thrilled to welcome Dr. Francis Tavares to our executive team as our Chief Technology Officer. Francis's extraordinary career, spanning over three decades in organic and medical chemistry, and drug discovery, adds invaluable expertise to PrevCeutical's leadership team. His unparalleled expertise in drug discovery, coupled with his proven ability to translate scientific innovation into commercial success, will be instrumental in advancing our mission to deliver transformative therapies in a wide array of disorders. We look forward to his insights as we continue to expand our impact in the health sciences sector."
Dr. Francis Tavare's Career Highlights:
Dr. Tavares is a distinguished leader in the biopharmaceutical industry, most recently serving as President and CEO of ChemoGenics BioPharma, where he spearheaded drug discovery initiatives. His leadership in developing small molecule inhibitors for kinases, proteases, and nuclear receptors has resulted in significant milestones, including the commercialization of Trilaciclib and the successful completion of Phase 3 clinical trials of Lerociclib, the best-in-class CDK4/6 inhibitor. With a robust track record of championing over 15 metabolic targets and leading multidisciplinary teams in medicinal chemistry, pharmacokinetics, and toxicology, Dr. Tavares has consistently delivered candidates for clinical trials.
Dr. Tavares holds a PhD in Organic Chemistry from Colorado State University and completed postdoctoral research at the University of Texas at Austin. His career includes key roles at GlaxoSmithKline (GSK), where he served as Group Manager in the Medicinal Chemistry Division and earned the Excellence in Science Award in 2004. As Founder of ChemoGenics BioPharma, he built state-of-the-art facilities and fostered collaborations that supported multiple Phase I and II SBIR grants, securing venture capital investment for commercialization.
Dr. Tavares remarked on his appointment:
"I am thrilled to step into the role as CTO at PreveCeutical Medical, where science and innovation converge to tackle some of the most challenging problems in drug discovery. I am excited to work alongside a team of world-class scientists, clinicians, and leaders to help bring transformative therapies to patients. Together, we'll strive to turn bold ideas into commercial products that will hugely benefit patients. These are very exciting times for PreveCeutical, and I am confident the corporate vision aligns very well for both patients and investors."
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On Behalf of the Board of Directors,
PreveCeutical Medical Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedarplus.ca. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257295
FAQ
Who is the new CTO of PreveCeutical Medical (PRVCF)?
What is Dr. Francis Tavares's background before joining PreveCeutical (PRVCF)?
What are Dr. Tavares's major achievements in drug development?
When did PreveCeutical (PRVCF) announce the appointment of their new CTO?
What is Dr. Tavares's educational background?
